Search
for
Sort by
Research 331–360 of 496
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients
- MicroRNA-Enriched Exosomes from Different Sources of Mesenchymal Stem Cells Can Differentially Modulate Functions of Immune Cells and Neurogenesis
- Phase II Evaluation of VDC‐1101 in Canine Cutaneous T‐Cell Lymphoma
- Alopecia and Associated Toxic Agents: A Systematic Review
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Expanding phenotype of hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis caused by FAM111B mutations: Report of an additional family raising the question of cancer predisposition and a short review of early-onset poikiloderma
- Minimizing Skin Scarring through Biomaterial Design
- Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- A medicinal and edible formula YH0618 ameliorates the toxicity induced by Doxorubicin via regulating the expression of Bax/Bcl-2 and FOXO4
- Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus
- Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
- The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19
- Prophylaxis and Management of Skin Toxicities
- Lithium: one drug, five complications
- A.S.P.E.N. Parenteral Nutrition Trace Element Product Shortage Considerations
- Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
- Role of anabolic agents in colorectal carcinogenesis: Myths and realities (Review)
- Further Insights in Trichothiodistrophy: A Clinical, Microscopic, and Ultrastructural Study of 20 Cases and Literature Review
- Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine
- Cell death in skin function, inflammation, and disease
- Management of Dermatologic Toxicities
- Skin manifestations associated with systemic diseases – Part I
- Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
- Use of Propolis for Topical Treatment of Dermatophytosis in Dog
- Chinese Herbal Medicine, Guilu Erxian Glue, as Alternative Medicine for Adverse Side Effects of Chemotherapy in Doxorubicin-Treated Cell and Mouse Models